Appointments

866.588.2264

Submit a Form

Questions

866.588.2264

Submit a Form

Expand Content

News

Recent news articles, press releases and videos surrounding Mellen Center for Multiple Sclerosis and the advancement of treatment options and research.

2012
New study reveals that individuals with benign MS show a distinct gene-activity pattern

Benign multiple sclerosis may sound like a contradiction in terms, but some patients live for decades with only mild symptoms. Whether neurologists can predict which people will develop this slow-motion form of MS remains controversial. Now, a new study reveals that individuals with benign MS show a distinct gene-activity pattern. In these people, a pathway essential for manufacturing proteins slows down and cell suicide climbs.

Experts disagree on controversial 'cure' for multiple sclerosis

In the last couple of decades, nine new drugs have come on the market to treat M.S.; at least four more are currently being tested on humans. Few diseases have seen such radical transformation of treatment options in such a short time. Yet for all the new options, many of the 2.1 million people worldwide afflicted with the disease (400,000 of them in the United States) have not seen improvements, and some M.S. patients find that the adverse reactions from the drugs aren’t worth the benefits.

Dr. Mary Rensel discusses a new study looking at statins and multiple sclerosis

High-dose simvastatin (Zocor) significantly reduced brain loss and slowed advancement of disability for 2 years in patients with secondary progressive multiple sclerosis.

Gilenya, an oral medication was approved by the US FDA to treat relapsing forms of MS

Gilenya is the first approved oral disease modifying treatment for MS. Combined data from a Phase II study and two Phase III trials showed that Gilenya reduces relapses, disability progression, MRI lesion activity, and brain atrophy progression (loss of brain tissue).

Read the full story on Gilenya for Multiple Sclerosis

What’s New in MS Research and Treatment

Dr. Fox was recently asked to talk about CCSVI and research into this topic on a National MS society webcast. Other MS researchers also comment on new directions in MS in this webcast. Dr. Fox's component is later in the program at 54 minutes.

Watch these videos to learn about recent improvements in treatment options and research.